MAP1LC3A and lung cancer: Indeed, EGFR-TKI-resistant (epidermal growth factor receptor-tyrosine kinase inhibitor) lung cancer cells presented a decreased methylation of the promoter of MAP1LC3v1 associated with increased LC3A protein expression [18].